Clarissa Pilkington
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Clarissa Pilkington has a total of 117 co-authors. Here are the top co-authors by number of shared publications:
- Angelo Ravelli
Direzione Scientifica, IRCCS Istituto Giannina Gaslini, Genova, Italy
3 shared publications - Charalampia Papadopoulou
Paediatric Rheumatology, Great Ormond Street Hospital for Children, NHS Foundation Trust , London
3 shared publications - Adam P. Croft
Rheumatology Research Group, Department of Inflammation and Ageing, College of Medicine & Health, University of Birmingham, Birmingham, UK
2 shared publications - Adele Civino
Pediatric Rheumatology and Immunology Unit, ‘Vito Fazzi’ Hospital, Italy
2 shared publications - Alessandro Consolaro
A. Consolaro, MD, PhD, UOC Reumatologia e Malattie Autoinfiammatorie, IRCCS Istituto Giannina Gaslini, Genoa, Italy; Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Università degli Studi di Genova, Genoa, Italy
2 shared publications - Angela Pistorio
Direzione Scientifica, IRCCS Istituto Giannina Gaslini , Genoa
2 shared publications
Latest Publications
- 13 April 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (5)
Introducing a parent-centred composite disease activity score for remote monitoring in juvenile dermatomyositis
Objectives: The objective of this study was to develop and test a composite DAS for JDM solely based on parent-reported outcomes (PROs). Methods: The parent JDM Activity Index (ParJDMAI) includes the following four PROs: (1) global assessment of disease activity; (2) assessment of fatigue; (3) assessment of muscle disease activity; (4) assessment of skin disease activity. Each item is weighted on a 0–10 scale, which yields a total score ranging from 0 to 40. Validation procedures were conducted on a multicentre sample of 254 patients with JDM according to the OMERACT filter for outcome measures in rheumatology. Results: The ParJDMAI is short and simple, and is quick, taking <10 minutes to complete and score, which makes it practical for use in standard clinical care. In validation analyses, the tool demonstrated good construct validity, satisfactory internal consistency (Cronbach’s alpha 0.86) and structure (with unambiguous identification of one factor with eigenvalue 2.9 on exploratory factor analysis), strong ability to discriminate between physician-estimated disease activity states (P < 0.001), and fair responsiveness to clinically important change over time (standardized response mean 0.8 among patients judged as improved by the parents). The ParJDMAI correlated strongly with physician-centred measures of disease activity. Conclusion: The ParJDMAI was found to be feasible and to possess good measurement properties. It also proved to potentially serve as a surrogate for physicians’ evaluations. Completion of the ParJDMAI through digital technologies may provide a reliable and pragmatic approach for building a remote patient-monitoring program.
- 13 April 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (5)
Introducing a parent-centred composite disease activity score for remote monitoring in juvenile dermatomyositis
Objectives: The objective of this study was to develop and test a composite DAS for JDM solely based on parent-reported outcomes (PROs). Methods: The parent JDM Activity Index (ParJDMAI) includes the following four PROs: (1) global assessment of disease activity; (2) assessment of fatigue; (3) assessment of muscle disease activity; (4) assessment of skin disease activity. Each item is weighted on a 0–10 scale, which yields a total score ranging from 0 to 40. Validation procedures were conducted on a multicentre sample of 254 patients with JDM according to the OMERACT filter for outcome measures in rheumatology. Results: The ParJDMAI is short and simple, and is quick, taking <10 minutes to complete and score, which makes it practical for use in standard clinical care. In validation analyses, the tool demonstrated good construct validity, satisfactory internal consistency (Cronbach’s alpha 0.86) and structure (with unambiguous identification of one factor with eigenvalue 2.9 on exploratory factor analysis), strong ability to discriminate between physician-estimated disease activity states (P < 0.001), and fair responsiveness to clinically important change over time (standardized response mean 0.8 among patients judged as improved by the parents). The ParJDMAI correlated strongly with physician-centred measures of disease activity. Conclusion: The ParJDMAI was found to be feasible and to possess good measurement properties. It also proved to potentially serve as a surrogate for physicians’ evaluations. Completion of the ParJDMAI through digital technologies may provide a reliable and pragmatic approach for building a remote patient-monitoring program.
- Open Access
- 9 August 2025
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 84 (10) , 1706-1720
Spatial transcriptomic analysis of muscle biopsy from patients with treatment-naive juvenile dermatomyositis reveals mitochondrial abnormalities despite disease-related interferon-driven signature
- 9 August 2025
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 84 (10) , 1706-1720
Open AccessSpatial transcriptomic analysis of muscle biopsy from patients with treatment-naive juvenile dermatomyositis reveals mitochondrial abnormalities despite disease-related interferon-driven signature
- Open Access
Spatial transcriptomic analysis of muscle biopsy from treatment-naive juvenile dermatomyositis patients reveals mitochondrial abnormalities despite disease-related interferon driven signature
Objectives: This study aimed to investigate the spatial transcriptomic landscape of muscle tissue from treatment-naïve juvenile dermatomyositis (JDM) patients in comparison to healthy paediatric muscle tissue. Methods: Muscle biopsies from three JDM patients and three age-matched controls were analysed using the Nanostring GeoMx® Digital Spatial Profiler. Regions of interest were selected based on muscle fibres without immune cells, immune cell infiltration and CD68+ macrophage enrichment. Differential gene expression, pathway analysis and pathways clustering analysis were conducted. Key findings were validated in 19 cases of JDM using immunohistochemistry and chemical stains, and a bulk RNAseq dataset of four cases of JDM. Results: JDM muscle tissues exhibited significant interferon pathway activation and mitochondrial dysfunction compared to controls. A 15-gene interferon signature was significantly elevated in JDM muscle and macrophage-enriched regions, correlating with clinical weakness. In contrast, mitochondrial dysregulation, characterized by downregulated respiratory chain pathways, was present regardless of interferon activity or muscle strength. The interferon-driven and mitochondrial signatures were replicated in an independent RNAseq dataset from JDM muscle; lack of association between interferon signature and mitochondrial dysregulation was validated in 19 cases by conventional staining methods. Clustering analysis revealed distinct transcriptomic profiles between JDM and control tissues, as well as between JDM patients with varying clinical phenotypes. Conclusions: This study highlights mitochondrial dysfunction as a consistent pathological feature in JDM muscle, which may be independent of interferon-driven inflammation. These findings highlight the potential for mitochondrial-targeted therapies in JDM management and emphasise the need for further studies to explore their therapeutic value. KEY MESSAGES: What is already known on this topic Juvenile dermatomyositis (JDM) involves interferon-driven inflammation and immune-mediated muscle damage. Mitochondrial abnormalities in blood immune cells persist despite treatment and contribute to disease pathology. What this study adds Mitochondrial dysfunction is present in both muscle fibres and tissue-infiltrating immune cells within JDM muscle. These abnormalities are detectable even in clinically less severe muscle weakness. Degree of mitochondrial abnormality at transcript and protein level may be independent of strength of IFN-driven signal. Mitochondrial dysregulation detected at transcriptional level correlates with abnormal transcription of muscle (sarcomere) and the subcellular peroxisome organelle. How this study might affect research, practice, or policy Targeting mitochondrial dysfunction could enhance treatment outcomes for JDM, especially in patients whose disease is refractory to current therapies. Insights from this study support the development of stratification tools to detect aspects of pathology which are not tightly correlated with IFN-driven pathology.
Open AccessSpatial transcriptomic analysis of muscle biopsy from treatment-naive juvenile dermatomyositis patients reveals mitochondrial abnormalities despite disease-related interferon driven signature
Objectives: This study aimed to investigate the spatial transcriptomic landscape of muscle tissue from treatment-naïve juvenile dermatomyositis (JDM) patients in comparison to healthy paediatric muscle tissue. Methods: Muscle biopsies from three JDM patients and three age-matched controls were analysed using the Nanostring GeoMx® Digital Spatial Profiler. Regions of interest were selected based on muscle fibres without immune cells, immune cell infiltration and CD68+ macrophage enrichment. Differential gene expression, pathway analysis and pathways clustering analysis were conducted. Key findings were validated in 19 cases of JDM using immunohistochemistry and chemical stains, and a bulk RNAseq dataset of four cases of JDM. Results: JDM muscle tissues exhibited significant interferon pathway activation and mitochondrial dysfunction compared to controls. A 15-gene interferon signature was significantly elevated in JDM muscle and macrophage-enriched regions, correlating with clinical weakness. In contrast, mitochondrial dysregulation, characterized by downregulated respiratory chain pathways, was present regardless of interferon activity or muscle strength. The interferon-driven and mitochondrial signatures were replicated in an independent RNAseq dataset from JDM muscle; lack of association between interferon signature and mitochondrial dysregulation was validated in 19 cases by conventional staining methods. Clustering analysis revealed distinct transcriptomic profiles between JDM and control tissues, as well as between JDM patients with varying clinical phenotypes. Conclusions: This study highlights mitochondrial dysfunction as a consistent pathological feature in JDM muscle, which may be independent of interferon-driven inflammation. These findings highlight the potential for mitochondrial-targeted therapies in JDM management and emphasise the need for further studies to explore their therapeutic value. KEY MESSAGES: What is already known on this topic Juvenile dermatomyositis (JDM) involves interferon-driven inflammation and immune-mediated muscle damage. Mitochondrial abnormalities in blood immune cells persist despite treatment and contribute to disease pathology. What this study adds Mitochondrial dysfunction is present in both muscle fibres and tissue-infiltrating immune cells within JDM muscle. These abnormalities are detectable even in clinically less severe muscle weakness. Degree of mitochondrial abnormality at transcript and protein level may be independent of strength of IFN-driven signal. Mitochondrial dysregulation detected at transcriptional level correlates with abnormal transcription of muscle (sarcomere) and the subcellular peroxisome organelle. How this study might affect research, practice, or policy Targeting mitochondrial dysfunction could enhance treatment outcomes for JDM, especially in patients whose disease is refractory to current therapies. Insights from this study support the development of stratification tools to detect aspects of pathology which are not tightly correlated with IFN-driven pathology.
- Open Access
- 14 July 2023
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 63 (5) , 1189-1191
Moving forward together: collaborative landscapes of research in idiopathic inflammatory myopathies and calcinosis
Lesley Ann Saketkoo, Antonia Valenzuela, Susan Kim, Liza J McCann, Christian Lood, Dawn M Wahezi, Victoria P Werth, Belina Yi, Helene Alexanderson, Susan Mailla
- 14 July 2023
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 63 (5) , 1189-1191
Open AccessMoving forward together: collaborative landscapes of research in idiopathic inflammatory myopathies and calcinosis
Lesley Ann Saketkoo, Antonia Valenzuela, Susan Kim, Liza J McCann, Christian Lood, Dawn M Wahezi, Victoria P Werth, Belina Yi, Helene Alexanderson, Susan Mailla
- Open Access
- 1 April 2023
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 62 (Supplement)
OA39 Development of a Childhood Lupus Low Disease Activity State definition: recommendations from the International Childhood Lupus Treat-to-Target Task Force
International interest in development of treat-to-target (T2T) in both childhood-onset systemic lupus erythematosus (cSLE) and adult-onset SLE (aSLE) is increasing. T2T could facilitate more effective and structured use of treatments, aggressively controlling disease activity, preventing organ damage, and improving health-related quality of life. The first step is the selection of an appropriate target. Remission is deemed the ultimate target, but may not be attainable by all. Low disease activity (LDA), based on the principle of “tolerable” disease activity on stable treatment, with low corticosteroid dosage, may be more appropriate for some patients. The aim of this study was to derive a consensus-based cSLE appropriate definition of LDA, building upon existing aSLE definitions to improve applicability to cSLE, whilst maintaining sufficient unity to ensure that future T2T studies including adolescents and adults together are possible. The International cSLE T2T Task Force, including 18 specialists from paediatric rheumatology/nephrology, and adult rheumatology undertook a series of Delphi surveys, exploring views on aSLE LDA targets. Two virtual consensus meetings were held, utilising a modified nominal group technique to debate, modify, and vote upon topics underpinning the cSLE LDA target and its criteria. Agreement of > 80% was considered consensus. The task force agreed that the LDA target should encompass cSLE as a whole and be based upon the aSLE Lupus Low Disease Activity State definition (LLDAS), with modifications to make it more applicable to cSLE (cLLDAS, all 100% agreement). A conceptual definition of cLLDAS was defined: ‘A state, which if sustained, is associated with a low likelihood of adverse outcome (considering disease activity, damage, and medication toxicity)’ (100% agreement). Five cLLDAS criteria were agreed, as detailed within Table 1. The final cLLDAS definition was endorsed by the Paediatric Rheumatology European Society (PReS) Executive Council and PReS cSLE Working Party Chair, on behalf of the Society. A cSLE, age-appropriate definition of cLLDAS has been generated, preserving sufficient unity with the aSLE LLDAS definition to encourage life-course research. The development and validation of targets has been a key enabler for T2T trials, therefore this initiative represents a significant step forward for cSLE. Disclosure E.M.D. Smith: None. A. Aggarwal: None. J. Ainsworth: None. E. Al-Abadi: None. T. Avcin: None. L. Bortey: None. J. Burnham: None. C. Ciurtin: None. C.M. Hedrich: None. S. Kamphuis: None. D. Levy: None. L. Lewandowski: None. N. Maxwell: None. E. Morand: None. S. Ozen: None. C. Pain: None. A. Ravelli: None. C. Saad Magalhaes: None. C. Pilkington: None. D. Schonenberg: None. C. Scott: None. K. Tullus: None. M.W. Beresford: None. Consensus cLLDAS definition 1) Haemolytic anaemia or GI involvement should be considered when scoring the PGA as these areas are not captured by the SLEDAI-2K. 2) 0 = no; 1 = mild; 2 = moderate; 3 = severe activity. 3) Lowest dose of the two options required for cLLDAS to be attained. Consensus cLLDAS definition 1) Haemolytic anaemia or GI involvement should be considered when scoring the PGA as these areas are not captured by the SLEDAI-2K. 2) 0 = no; 1 = mild; 2 = moderate; 3 = severe activity. 3) Lowest dose of the two options required for cLLDAS to be attained.
- 1 April 2023
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 62 (Supplement)
Open AccessOA39 Development of a Childhood Lupus Low Disease Activity State definition: recommendations from the International Childhood Lupus Treat-to-Target Task Force
International interest in development of treat-to-target (T2T) in both childhood-onset systemic lupus erythematosus (cSLE) and adult-onset SLE (aSLE) is increasing. T2T could facilitate more effective and structured use of treatments, aggressively controlling disease activity, preventing organ damage, and improving health-related quality of life. The first step is the selection of an appropriate target. Remission is deemed the ultimate target, but may not be attainable by all. Low disease activity (LDA), based on the principle of “tolerable” disease activity on stable treatment, with low corticosteroid dosage, may be more appropriate for some patients. The aim of this study was to derive a consensus-based cSLE appropriate definition of LDA, building upon existing aSLE definitions to improve applicability to cSLE, whilst maintaining sufficient unity to ensure that future T2T studies including adolescents and adults together are possible. The International cSLE T2T Task Force, including 18 specialists from paediatric rheumatology/nephrology, and adult rheumatology undertook a series of Delphi surveys, exploring views on aSLE LDA targets. Two virtual consensus meetings were held, utilising a modified nominal group technique to debate, modify, and vote upon topics underpinning the cSLE LDA target and its criteria. Agreement of > 80% was considered consensus. The task force agreed that the LDA target should encompass cSLE as a whole and be based upon the aSLE Lupus Low Disease Activity State definition (LLDAS), with modifications to make it more applicable to cSLE (cLLDAS, all 100% agreement). A conceptual definition of cLLDAS was defined: ‘A state, which if sustained, is associated with a low likelihood of adverse outcome (considering disease activity, damage, and medication toxicity)’ (100% agreement). Five cLLDAS criteria were agreed, as detailed within Table 1. The final cLLDAS definition was endorsed by the Paediatric Rheumatology European Society (PReS) Executive Council and PReS cSLE Working Party Chair, on behalf of the Society. A cSLE, age-appropriate definition of cLLDAS has been generated, preserving sufficient unity with the aSLE LLDAS definition to encourage life-course research. The development and validation of targets has been a key enabler for T2T trials, therefore this initiative represents a significant step forward for cSLE. Disclosure E.M.D. Smith: None. A. Aggarwal: None. J. Ainsworth: None. E. Al-Abadi: None. T. Avcin: None. L. Bortey: None. J. Burnham: None. C. Ciurtin: None. C.M. Hedrich: None. S. Kamphuis: None. D. Levy: None. L. Lewandowski: None. N. Maxwell: None. E. Morand: None. S. Ozen: None. C. Pain: None. A. Ravelli: None. C. Saad Magalhaes: None. C. Pilkington: None. D. Schonenberg: None. C. Scott: None. K. Tullus: None. M.W. Beresford: None. Consensus cLLDAS definition 1) Haemolytic anaemia or GI involvement should be considered when scoring the PGA as these areas are not captured by the SLEDAI-2K. 2) 0 = no; 1 = mild; 2 = moderate; 3 = severe activity. 3) Lowest dose of the two options required for cLLDAS to be attained. Consensus cLLDAS definition 1) Haemolytic anaemia or GI involvement should be considered when scoring the PGA as these areas are not captured by the SLEDAI-2K. 2) 0 = no; 1 = mild; 2 = moderate; 3 = severe activity. 3) Lowest dose of the two options required for cLLDAS to be attained.
- Open Access
- 28 September 2022
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 6 (Supplement)
OA05 Clinical presentation, risk factors and prognosis of MDA5-positive JDM; clinical diversity and red flags
MDA5-positive juvenile dermatomyositis (JDM) represents a distinct clinical phenotype associated with skin and oral ulceration, milder muscle involvement and a higher incidence of interstitial lung disease (ILD) and severe rapidly progressive ILD (RP-ILD). The objectives were to describe the presenting clinical characteristics of patients with MDA5-positive JDM, the incidence of ILD and risk factors associated with development of RP-ILD. Retrospective clinical notes review of patients with MDA5-positive JDM managed at Great Ormond Street Hospital (GOSH) over a 24-year period. Twenty-five patients were managed at our centre with MDA5-positive JDM. One additional patient was excluded as no notes available. Sixty-four % females. Sixty % were White British, 20% Black African, 8% Mixed, 8% Asian, 8% European and 4% South Asian. Median age of presentation was 10.0 years (IQR 6.9,12.3). Diagnostic delay was significant, with median 14 weeks (8,26) between initial symptoms and diagnosis. 24% of this cohort were also Ro-52 positive. Presentation: All patients had skin involvement; 52% ulcerating skin disease, 64% heliotrope rash and 100% Gottrons papules on initial presentation. Forty-four % had peri-ungal changes, 35% digital pitting/infarcts and 64% nailfold changes. 40% had peri-orbital oedema. Muscle involvement was present in all, with median CMAS 40/52 (36,44) and MMT8 57/80 (51,62). Eighty-eight % had arthritis; initial active joint count was available for 16 patients with median 5.5 joints (3,16). 40% had gastrointestinal symptoms; fever, weight loss and mouth ulcers were present in 52%, 52% and 60% respectively. Twenty-four % had respiratory symptoms at diagnosis. Interstitial lung disease: 52% were diagnosed with ILD and a further 20% had abnormal pulmonary CT scans not thought to be diagnostic of ILD. 13% (2 patients) had RP-ILD; both of whom died despite immunosuppression and extracorporeal membrane oxygenation. There were no other deaths amongst this cohort. No respiratory involvement was identified in 28%. Of 19 patients who had a CT chest at diagnosis, 84% were abnormal. Only 1 patient developed respiratory involvement during disease course whilst on treatment; the other 93% with ILD had evidence of ILD at diagnosis. Out of 58 putative variables, 4 risk factors were associated with development of RP-ILD which reached statistical significance, a further 3 factors were significantly protective, as is shown in Table 1. 2 patients had pneumocystis pneumonia (PCP), both of whom required intensive care and one associated with death. shows risk factors at presentation which were found to be significantly associated with RP-ILD shows risk factors at presentation which were found to be significantly associated with RP-ILD Skin and muscle involvement were identified in all patients, with the majority also presenting with ulcerating skin disease, oral ulceration and arthritis. The majority of this cohort had lung involvement and 2 patients died of RP-ILD. Four risk factors were found to be predictive of RP-ILD and a further 3 protective factors were identified. Rapid deterioration of respiratory symptoms was associated with PCP, while ILD was unlikely to develop whilst on treatment if not present at diagnosis. These findings need to be validated in a larger cohort of patients.
- 28 September 2022
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 6 (Supplement)
Open AccessOA05 Clinical presentation, risk factors and prognosis of MDA5-positive JDM; clinical diversity and red flags
MDA5-positive juvenile dermatomyositis (JDM) represents a distinct clinical phenotype associated with skin and oral ulceration, milder muscle involvement and a higher incidence of interstitial lung disease (ILD) and severe rapidly progressive ILD (RP-ILD). The objectives were to describe the presenting clinical characteristics of patients with MDA5-positive JDM, the incidence of ILD and risk factors associated with development of RP-ILD. Retrospective clinical notes review of patients with MDA5-positive JDM managed at Great Ormond Street Hospital (GOSH) over a 24-year period. Twenty-five patients were managed at our centre with MDA5-positive JDM. One additional patient was excluded as no notes available. Sixty-four % females. Sixty % were White British, 20% Black African, 8% Mixed, 8% Asian, 8% European and 4% South Asian. Median age of presentation was 10.0 years (IQR 6.9,12.3). Diagnostic delay was significant, with median 14 weeks (8,26) between initial symptoms and diagnosis. 24% of this cohort were also Ro-52 positive. Presentation: All patients had skin involvement; 52% ulcerating skin disease, 64% heliotrope rash and 100% Gottrons papules on initial presentation. Forty-four % had peri-ungal changes, 35% digital pitting/infarcts and 64% nailfold changes. 40% had peri-orbital oedema. Muscle involvement was present in all, with median CMAS 40/52 (36,44) and MMT8 57/80 (51,62). Eighty-eight % had arthritis; initial active joint count was available for 16 patients with median 5.5 joints (3,16). 40% had gastrointestinal symptoms; fever, weight loss and mouth ulcers were present in 52%, 52% and 60% respectively. Twenty-four % had respiratory symptoms at diagnosis. Interstitial lung disease: 52% were diagnosed with ILD and a further 20% had abnormal pulmonary CT scans not thought to be diagnostic of ILD. 13% (2 patients) had RP-ILD; both of whom died despite immunosuppression and extracorporeal membrane oxygenation. There were no other deaths amongst this cohort. No respiratory involvement was identified in 28%. Of 19 patients who had a CT chest at diagnosis, 84% were abnormal. Only 1 patient developed respiratory involvement during disease course whilst on treatment; the other 93% with ILD had evidence of ILD at diagnosis. Out of 58 putative variables, 4 risk factors were associated with development of RP-ILD which reached statistical significance, a further 3 factors were significantly protective, as is shown in Table 1. 2 patients had pneumocystis pneumonia (PCP), both of whom required intensive care and one associated with death. shows risk factors at presentation which were found to be significantly associated with RP-ILD shows risk factors at presentation which were found to be significantly associated with RP-ILD Skin and muscle involvement were identified in all patients, with the majority also presenting with ulcerating skin disease, oral ulceration and arthritis. The majority of this cohort had lung involvement and 2 patients died of RP-ILD. Four risk factors were found to be predictive of RP-ILD and a further 3 protective factors were identified. Rapid deterioration of respiratory symptoms was associated with PCP, while ILD was unlikely to develop whilst on treatment if not present at diagnosis. These findings need to be validated in a larger cohort of patients.
- Open Access
Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison
Objective To assess the efficacy and safety of belimumab in paediatric versus adult patients with systemic lupus erythematosus (SLE). Methods We performed across-study comparisons of patients with active SLE who received belimumab or placebo, plus standard therapy, in PLUTO (paediatric phase II) and BLISS-52, BLISS-76, BLISS-NEA and EMBRACE (adult phase III). Analysed efficacy data included Week 52 SLE Responder Index (SRI)-4 response rate (EMBRACE: SRI with modified Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) proteinuria scoring (SRI-S2K)); SRI-4 response rate (EMBRACE: SRI-S2K) according to baseline disease activity indicators (Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score; anti-dsDNA/C3/C4 levels); Week 52 SRI-6 response rate; and time to first severe flare (SELENA-SLEDAI Flare Index) over 52 weeks. Safety data were compared for all aforementioned studies along with adult LBSL02 (phase II) and BLISS-SC (phase III). Results SRI-4 response rates were similar across the paediatric and adult studies; more belimumab-treated patients achieved SRI-4 responses versus placebo (PLUTO: 52.8% vs 43.6%; BLISS-52: 57.6% vs 43.6%; BLISS-76: 43.2% vs 33.8%; BLISS-NEA: 53.8% vs 40.1%; EMBRACE: 48.7% vs 41.6%). Across all studies, SRI-4 response rates were generally greater in patients with baseline SELENA-SLEDAI scores ≥10 than in patients with baseline SELENA-SLEDAI scores ≤9. A similar proportion of belimumab-treated patients achieved SRI-6 across all studies (PLUTO: 41.2%; BLISS-52: 46.2%; BLISS-76: 33.1%; BLISS-NEA: 43.9%; EMBRACE: 37.5%). Belimumab reduced the risk of severe flare versus placebo in all studies. The incidence of adverse events was similar across all studies. Conclusions These analyses demonstrate consistent efficacy and safety of belimumab plus standard therapy across paediatric and adult patients with SLE. Trial registration numbers PLUTO (NCT01649765); BLISS-52 (NCT00424476); BLISS-76 (NCT00410384); BLISS-NEA (NCT01345253); EMBRACE (NCT01632241); BLISS-SC (NCT01484496); and LBSL02 (NCT00071487).
Open AccessEfficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison
Objective To assess the efficacy and safety of belimumab in paediatric versus adult patients with systemic lupus erythematosus (SLE). Methods We performed across-study comparisons of patients with active SLE who received belimumab or placebo, plus standard therapy, in PLUTO (paediatric phase II) and BLISS-52, BLISS-76, BLISS-NEA and EMBRACE (adult phase III). Analysed efficacy data included Week 52 SLE Responder Index (SRI)-4 response rate (EMBRACE: SRI with modified Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) proteinuria scoring (SRI-S2K)); SRI-4 response rate (EMBRACE: SRI-S2K) according to baseline disease activity indicators (Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score; anti-dsDNA/C3/C4 levels); Week 52 SRI-6 response rate; and time to first severe flare (SELENA-SLEDAI Flare Index) over 52 weeks. Safety data were compared for all aforementioned studies along with adult LBSL02 (phase II) and BLISS-SC (phase III). Results SRI-4 response rates were similar across the paediatric and adult studies; more belimumab-treated patients achieved SRI-4 responses versus placebo (PLUTO: 52.8% vs 43.6%; BLISS-52: 57.6% vs 43.6%; BLISS-76: 43.2% vs 33.8%; BLISS-NEA: 53.8% vs 40.1%; EMBRACE: 48.7% vs 41.6%). Across all studies, SRI-4 response rates were generally greater in patients with baseline SELENA-SLEDAI scores ≥10 than in patients with baseline SELENA-SLEDAI scores ≤9. A similar proportion of belimumab-treated patients achieved SRI-6 across all studies (PLUTO: 41.2%; BLISS-52: 46.2%; BLISS-76: 33.1%; BLISS-NEA: 43.9%; EMBRACE: 37.5%). Belimumab reduced the risk of severe flare versus placebo in all studies. The incidence of adverse events was similar across all studies. Conclusions These analyses demonstrate consistent efficacy and safety of belimumab plus standard therapy across paediatric and adult patients with SLE. Trial registration numbers PLUTO (NCT01649765); BLISS-52 (NCT00424476); BLISS-76 (NCT00410384); BLISS-NEA (NCT01345253); EMBRACE (NCT01632241); BLISS-SC (NCT01484496); and LBSL02 (NCT00071487).
- 15 November 2020
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 48 (6) , 898-906
Development and Testing of Reduced Versions of the Manual Muscle Test-8 in Juvenile Dermatomyositis
Objective.: To develop and test shortened versions of the Manual Muscle Test-8 (MMT-8) in juvenile dermatomyositis (JDM).Methods.: Construction of reduced tools was based on a retrospective analysis of individual scores of MMT-8 muscle groups in 3 multinational datasets. The 4 and 6 most frequently impaired muscle groups were included in MMT-4 and MMT-6, respectively. Metrologic properties of reduced tools were assessed by evaluating construct validity, internal consistency, discriminant ability, and responsiveness to change.Results.: Neck flexors, hip extensors, hip abductors, and shoulder abductors were included in MMT-4, whereas MMT-6 also included elbow flexors and hip flexors. Both shortened tools revealed strong correlations with MMT-8 and other muscle strength measures. Correlations with other JDM outcome measures were in line with predictions. Internal consistency was good (0.88–0.96) for both MMT-4 and MMT-6. Both reduced tools showed strong ability to discriminate between disease activity states, assessed by the caring physician or a parent (P< 0.001), and between patients whose parents were satisfied or not satisfied with illness course (P< 0.001). Responsiveness to change (assessed by both standardized response mean and relative efficiency) of MMT-4 and, to a lesser degree, MMT-6, was slightly superior to that of MMT-8.Conclusion.: Overall, the metrologic performance of MMT-4 and MMT-6 was comparable to that of the other established muscle strength tools, which indicates that they may be suitable for use in clinical practice and research, including clinical trials. The measurement properties of these tools should be further tested in other patient populations and evaluated prospectively.
- 15 November 2020
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 48 (6) , 898-906
Development and Testing of Reduced Versions of the Manual Muscle Test-8 in Juvenile Dermatomyositis
Objective.: To develop and test shortened versions of the Manual Muscle Test-8 (MMT-8) in juvenile dermatomyositis (JDM).Methods.: Construction of reduced tools was based on a retrospective analysis of individual scores of MMT-8 muscle groups in 3 multinational datasets. The 4 and 6 most frequently impaired muscle groups were included in MMT-4 and MMT-6, respectively. Metrologic properties of reduced tools were assessed by evaluating construct validity, internal consistency, discriminant ability, and responsiveness to change.Results.: Neck flexors, hip extensors, hip abductors, and shoulder abductors were included in MMT-4, whereas MMT-6 also included elbow flexors and hip flexors. Both shortened tools revealed strong correlations with MMT-8 and other muscle strength measures. Correlations with other JDM outcome measures were in line with predictions. Internal consistency was good (0.88–0.96) for both MMT-4 and MMT-6. Both reduced tools showed strong ability to discriminate between disease activity states, assessed by the caring physician or a parent (P< 0.001), and between patients whose parents were satisfied or not satisfied with illness course (P< 0.001). Responsiveness to change (assessed by both standardized response mean and relative efficiency) of MMT-4 and, to a lesser degree, MMT-6, was slightly superior to that of MMT-8.Conclusion.: Overall, the metrologic performance of MMT-4 and MMT-6 was comparable to that of the other established muscle strength tools, which indicates that they may be suitable for use in clinical practice and research, including clinical trials. The measurement properties of these tools should be further tested in other patient populations and evaluated prospectively.